Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alpha-Cyclodextrin
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Acinonyx Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Lindus Health Launches Acne Trial with Acinonyx Bio Evaluating Alternative Treatment
Details : The collaboration aims to conduct the clinical development of ACX, which is evaluating their topical cream's ability to treat patients with moderate to severe inflammatory acne.
Brand Name : ACX
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
May 16, 2024
Lead Product(s) : Alpha-Cyclodextrin
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Acinonyx Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $15.3 million
Deal Type : Public Offering
Evgen Pharma Announces Placing and Open Offer to raise up to £11 million
Details : The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.
Brand Name : SFX-01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 02, 2021
Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $15.3 million
Deal Type : Public Offering
Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : University of Dundee
Deal Size : Not Applicable
Deal Type : Not Applicable
Evgen Pharma Provides Patient Recruitment Update in STAR-COVID 19 Trial
Details : A total of 56 patients had been recruited and randomised to the STAR trial ("SFX-01 treatment for Acute Respiratory Infections").SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress.
Brand Name : SFX-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 19, 2021
Lead Product(s) : Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : University of Dundee
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?